Analysts at Leerink Partners Maintain their Past ‘”Hold”’ rating on Shares Ascendis Pharma (NASDAQ:ASND), Set a $70.0000 Target Price

June 1, 2018 - By Adrian Mccoy

Ascendis Pharma (NASDAQ:ASND) Rating Reaffirmed

Leerink Partners now has a $70.0000 target on shares of Ascendis Pharma (NASDAQ:ASND). The target would indicate a potential downside of -2.80 % from the previous close of Ascendis Pharma (NASDAQ:ASND). This rating was released in analysts report on Thursday, 31 May.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Coverage

Among 4 analysts covering Ascendis Pharma (NASDAQ:ASND), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Ascendis Pharma has $7900 highest and $50.0 lowest target. $73.25’s average target is 1.71% above currents $72.02 stock price. Ascendis Pharma had 12 analyst reports since January 3, 2018 according to SRatingsIntel. The company was maintained on Monday, May 14 by J.P. Morgan. Credit Suisse maintained it with “Buy” rating and $50.0 target in Thursday, February 22 report. The stock of Ascendis Pharma A/S (NASDAQ:ASND) has “Buy” rating given on Tuesday, February 6 by Wedbush. Wedbush maintained the shares of ASND in report on Monday, February 26 with “Buy” rating. The firm has “Buy” rating given on Thursday, January 25 by Bank of America. On Monday, March 19 the stock rating was maintained by Wedbush with “Buy”. The company was maintained on Tuesday, March 20 by Credit Suisse. The firm has “Buy” rating given on Tuesday, May 15 by Wedbush. J.P. Morgan maintained the stock with “Buy” rating in Wednesday, January 17 report. Wedbush maintained the stock with “Buy” rating in Wednesday, April 4 report.

The stock decreased 1.67% or $1.22 during the last trading session, reaching $72.02. About 261,376 shares traded or 99.98% up from the average. Ascendis Pharma A/S (NASDAQ:ASND) has risen 178.35% since June 1, 2017 and is uptrending. It has outperformed by 165.78% the S&P500.

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. The company has market cap of $2.99 billion. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. It currently has negative earnings. The firm is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

More notable recent Ascendis Pharma A/S (NASDAQ:ASND) news were published by: Globenewswire.com which released: “Ascendis Pharma A/S Reports First Quarter 2018 Financial Results” on May 30, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: Clinical Hold For Crispr, Gilead Study Meets Endpoint, Akers Gets Grace Time” published on May 31, 2018, Benzinga.com published: “The Week Ahead In Biotech: ASCO Presentations In The Spotlight” on May 26, 2018. More interesting news about Ascendis Pharma A/S (NASDAQ:ASND) were released by: Nasdaq.com and their article: “Ascendis Pharma A/S Announces First Quarter 2018 Financial Results and Business Update Conference Call on May 30” published on May 10, 2018 as well as Nasdaq.com‘s news article titled: “Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of TransCon CNP” with publication date: May 08, 2018.

Ascendis Pharma A/S (NASDAQ:ASND) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.